Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol for retinal and CNS hemangioblastomas in von Hippel–Lindau disease
2014-003671-30Phase 3Completed
- Sponsor
- Alianza Española de Familias de Von Hippel-Lindau
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of propranolol in von Hippel–Lindau disease (VHL), retinal haemangioma and Haemangioblastoma, sponsored by Alianza Española de Familias de Von Hippel-Lindau. Primary endpoint: NUMBER AND SIZE OF THE RETINAL HEMANGIOBLASTOMAS. Started Sep 2014; status: completed.
02
Drugs
propranolol
03
Conditions
von Hippel–Lindau disease (VHL)retinal haemangiomaHaemangioblastoma
Beyond the preview
Go deeper on 2014-003671-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003671-30.